Finding 1150945 (2023-005)

Significant Deficiency
Requirement
AB
Questioned Costs
-
Year
2023
Accepted
2025-08-22
Audit: 364802

AI Summary

  • Core Issue: Lack of internal controls for reviewing fringe benefit journal entries may lead to unallowable expenses being charged to federal research grants.
  • Impacted Requirements: This finding violates Section 200.303 of the Uniform Guidance, which mandates effective internal controls over federal awards.
  • Recommended Follow-Up: Management should implement revised policies to ensure proper review and approval of fringe benefit journal entries annually.

Finding Text

Finding 2023-005 – Activities Allowed or Unallowed and Allowable Costs/Cost PrinciplesIdentification of the federal program:Federal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.172, Human Genome ResearchPass-Through Grantor: University of ChicagoFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.242, Mental Health Research GrantsPass-Through Grantors: Rutgers State University, University of Chicago, Johns Hopkins UniversityFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.307, Minority Health and Health Disparities ResearchPass-Through Grantor: Northwestern UniversityFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.350, National Center for Advancing Translational SciencesPass-Through Grantors: University of Chicago, Duke UniversityFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.361, Nursing ResearchPass-Through Grantor: Northwestern UniversityFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.395, Cancer Treatment ResearchFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.847, Diabetes, Digestive, and Kidney Diseases Extramural ResearchPass-Through Grantors: Northwestern University, Duke University, University of Washington, The Regents of the University of MichiganFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.855, Allergy, Immunology and Transplantation ResearchPass-Through Grantor: Northwestern UniversityFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.865, Child Health and Human Development Extramural ResearchPass-Through Grantor: University of ChicagoFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.946, Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative ProgramsPass-Through Grantor: Northwestern UniversityCriteria or specific requirement (including statutory, regulatory or other citation):Section 200.303 of the Uniform Guidance states the following regarding internal control: “The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”Condition:Management develops a fringe benefit rate annually that is used to allocate fringe benefits to the research and development programs from January 1, 2023 to December 31, 2023. Management did not have internal controls to review the appropriateness of the journal entries for fringe benefit rates.Cause:Management does not have internal controls and policies and procedures to require an appropriate review of fringe benefit journal entries.Effect or potential effect:Unallowable expenses may be inappropriately applied to research and development grants.Questioned costs:None.Context:We tested a sample of 16 fringe benefit journal entries to review. Based on the procedures performed, we identified that the fringe benefit costs were not reviewed timely by the appropriate individual. The Company incurred $673,983 of fringe benefits in 2023 related to Research and Development grants that are included on the Schedule of Expenditures of Federal Awards. Total federal expenditures related to the research and development cluster were $13,409,825 for the year ended December 31, 2023.Identification as a repeat finding, if applicable:This finding is not a repeat finding from the prior year.Recommendation:Management should revise its internal controls and policies to require the appropriate review and approval of fringe benefit journal entries.Views of responsible officials:Management will document a policy to review the updated fringe rate on an annual basis and ensure the fringe expense charged to the grants is in line with the policy and the calculated rate.

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 574483 2023-001
    Material Weakness
  • 574484 2023-002
    Material Weakness
  • 574485 2023-001
    Material Weakness
  • 574486 2023-002
    Material Weakness
  • 574487 2023-001
    Material Weakness
  • 574488 2023-005
    Significant Deficiency
  • 574489 2023-001
    Material Weakness
  • 574490 2023-005
    Significant Deficiency
  • 574491 2023-001
    Material Weakness
  • 574492 2023-002
    Material Weakness
  • 574493 2023-005
    Significant Deficiency
  • 574494 2023-005
    Significant Deficiency
  • 574495 2023-001
    Material Weakness
  • 574496 2023-005
    Significant Deficiency
  • 574497 2023-001
    Material Weakness
  • 574498 2023-001
    Material Weakness
  • 574499 2023-002
    Material Weakness
  • 574500 2023-005
    Significant Deficiency
  • 574501 2023-001
    Material Weakness
  • 574502 2023-002
    Material Weakness
  • 574503 2023-005
    Significant Deficiency
  • 574504 2023-005
    Significant Deficiency
  • 574505 2023-001
    Material Weakness
  • 574506 2023-001
    Material Weakness
  • 574507 2023-005
    Significant Deficiency
  • 574508 2023-001
    Material Weakness
  • 574509 2023-002
    Material Weakness
  • 574510 2023-004
    Material Weakness
  • 574511 2023-001
    Material Weakness
  • 574512 2023-001
    Material Weakness
  • 574513 2023-005
    Significant Deficiency
  • 574514 2023-001
    Material Weakness
  • 574515 2023-005
    Significant Deficiency
  • 574516 2023-001
    Material Weakness
  • 574517 2023-005
    Significant Deficiency
  • 574518 2023-001
    Material Weakness
  • 574519 2023-005
    Significant Deficiency
  • 574520 2023-001
    Material Weakness
  • 574521 2023-005
    Significant Deficiency
  • 574522 2023-001
    Material Weakness
  • 574523 2023-005
    Significant Deficiency
  • 574524 2023-001
    Material Weakness
  • 574525 2023-005
    Significant Deficiency
  • 574526 2023-001
    Material Weakness
  • 574527 2023-005
    Significant Deficiency
  • 574528 2023-001
    Material Weakness
  • 574529 2023-005
    Significant Deficiency
  • 574530 2023-001
    Material Weakness
  • 574531 2023-005
    Significant Deficiency
  • 574532 2023-001
    Material Weakness
  • 574533 2023-005
    Significant Deficiency
  • 574534 2023-001
    Material Weakness
  • 574535 2023-005
    Significant Deficiency
  • 574536 2023-001
    Material Weakness
  • 574537 2023-001
    Material Weakness
  • 574538 2023-001
    Material Weakness
  • 574539 2023-001
    Material Weakness
  • 574540 2023-001
    Material Weakness
  • 574541 2023-001
    Material Weakness
  • 574542 2023-002
    Material Weakness
  • 574543 2023-003
    Material Weakness
  • 574544 2023-002
    Material Weakness
  • 574545 2023-001
    Material Weakness
  • 574546 2023-001
    Material Weakness
  • 574547 2023-005
    Significant Deficiency
  • 574548 2023-001
    Material Weakness
  • 574549 2023-005
    Significant Deficiency
  • 574550 2023-001
    Material Weakness
  • 574551 2023-005
    Significant Deficiency
  • 574552 2023-001
    Material Weakness
  • 574553 2023-002
    Material Weakness
  • 574554 2023-005
    Significant Deficiency
  • 574555 2023-001
    Material Weakness
  • 574556 2023-005
    Significant Deficiency
  • 574557 2023-001
    Material Weakness
  • 574558 2023-005
    Significant Deficiency
  • 574559 2023-001
    Material Weakness
  • 574560 2023-002
    Material Weakness
  • 574561 2023-001
    Material Weakness
  • 574562 2023-002
    Material Weakness
  • 574563 2023-001
    Material Weakness
  • 574564 2023-005
    Significant Deficiency
  • 574565 2023-002
    Material Weakness
  • 574566 2023-001
    Material Weakness
  • 574567 2023-002
    Material Weakness
  • 574568 2023-001
    Material Weakness
  • 574569 2023-001
    Material Weakness
  • 574570 2023-001
    Material Weakness
  • 574571 2023-005
    Significant Deficiency
  • 574572 2023-001
    Material Weakness
  • 574573 2023-001
    Material Weakness
  • 574574 2023-003
    Material Weakness
  • 574575 2023-001
    Material Weakness
  • 574576 2023-002
    Material Weakness
  • 574577 2023-005
    Significant Deficiency
  • 574578 2023-001
    Material Weakness
  • 574579 2023-002
    Material Weakness
  • 574580 2023-005
    Significant Deficiency
  • 574581 2023-001
    Material Weakness
  • 574582 2023-006
    Material Weakness
  • 574583 2023-001
    Material Weakness
  • 574584 2023-006
    Material Weakness
  • 1150925 2023-001
    Material Weakness
  • 1150926 2023-002
    Material Weakness
  • 1150927 2023-001
    Material Weakness
  • 1150928 2023-002
    Material Weakness
  • 1150929 2023-001
    Material Weakness
  • 1150930 2023-005
    Significant Deficiency
  • 1150931 2023-001
    Material Weakness
  • 1150932 2023-005
    Significant Deficiency
  • 1150933 2023-001
    Material Weakness
  • 1150934 2023-002
    Material Weakness
  • 1150935 2023-005
    Significant Deficiency
  • 1150936 2023-005
    Significant Deficiency
  • 1150937 2023-001
    Material Weakness
  • 1150938 2023-005
    Significant Deficiency
  • 1150939 2023-001
    Material Weakness
  • 1150940 2023-001
    Material Weakness
  • 1150941 2023-002
    Material Weakness
  • 1150942 2023-005
    Significant Deficiency
  • 1150943 2023-001
    Material Weakness
  • 1150944 2023-002
    Material Weakness
  • 1150946 2023-005
    Significant Deficiency
  • 1150947 2023-001
    Material Weakness
  • 1150948 2023-001
    Material Weakness
  • 1150949 2023-005
    Significant Deficiency
  • 1150950 2023-001
    Material Weakness
  • 1150951 2023-002
    Material Weakness
  • 1150952 2023-004
    Material Weakness
  • 1150953 2023-001
    Material Weakness
  • 1150954 2023-001
    Material Weakness
  • 1150955 2023-005
    Significant Deficiency
  • 1150956 2023-001
    Material Weakness
  • 1150957 2023-005
    Significant Deficiency
  • 1150958 2023-001
    Material Weakness
  • 1150959 2023-005
    Significant Deficiency
  • 1150960 2023-001
    Material Weakness
  • 1150961 2023-005
    Significant Deficiency
  • 1150962 2023-001
    Material Weakness
  • 1150963 2023-005
    Significant Deficiency
  • 1150964 2023-001
    Material Weakness
  • 1150965 2023-005
    Significant Deficiency
  • 1150966 2023-001
    Material Weakness
  • 1150967 2023-005
    Significant Deficiency
  • 1150968 2023-001
    Material Weakness
  • 1150969 2023-005
    Significant Deficiency
  • 1150970 2023-001
    Material Weakness
  • 1150971 2023-005
    Significant Deficiency
  • 1150972 2023-001
    Material Weakness
  • 1150973 2023-005
    Significant Deficiency
  • 1150974 2023-001
    Material Weakness
  • 1150975 2023-005
    Significant Deficiency
  • 1150976 2023-001
    Material Weakness
  • 1150977 2023-005
    Significant Deficiency
  • 1150978 2023-001
    Material Weakness
  • 1150979 2023-001
    Material Weakness
  • 1150980 2023-001
    Material Weakness
  • 1150981 2023-001
    Material Weakness
  • 1150982 2023-001
    Material Weakness
  • 1150983 2023-001
    Material Weakness
  • 1150984 2023-002
    Material Weakness
  • 1150985 2023-003
    Material Weakness
  • 1150986 2023-002
    Material Weakness
  • 1150987 2023-001
    Material Weakness
  • 1150988 2023-001
    Material Weakness
  • 1150989 2023-005
    Significant Deficiency
  • 1150990 2023-001
    Material Weakness
  • 1150991 2023-005
    Significant Deficiency
  • 1150992 2023-001
    Material Weakness
  • 1150993 2023-005
    Significant Deficiency
  • 1150994 2023-001
    Material Weakness
  • 1150995 2023-002
    Material Weakness
  • 1150996 2023-005
    Significant Deficiency
  • 1150997 2023-001
    Material Weakness
  • 1150998 2023-005
    Significant Deficiency
  • 1150999 2023-001
    Material Weakness
  • 1151000 2023-005
    Significant Deficiency
  • 1151001 2023-001
    Material Weakness
  • 1151002 2023-002
    Material Weakness
  • 1151003 2023-001
    Material Weakness
  • 1151004 2023-002
    Material Weakness
  • 1151005 2023-001
    Material Weakness
  • 1151006 2023-005
    Significant Deficiency
  • 1151007 2023-002
    Material Weakness
  • 1151008 2023-001
    Material Weakness
  • 1151009 2023-002
    Material Weakness
  • 1151010 2023-001
    Material Weakness
  • 1151011 2023-001
    Material Weakness
  • 1151012 2023-001
    Material Weakness
  • 1151013 2023-005
    Significant Deficiency
  • 1151014 2023-001
    Material Weakness
  • 1151015 2023-001
    Material Weakness
  • 1151016 2023-003
    Material Weakness
  • 1151017 2023-001
    Material Weakness
  • 1151018 2023-002
    Material Weakness
  • 1151019 2023-005
    Significant Deficiency
  • 1151020 2023-001
    Material Weakness
  • 1151021 2023-002
    Material Weakness
  • 1151022 2023-005
    Significant Deficiency
  • 1151023 2023-001
    Material Weakness
  • 1151024 2023-006
    Material Weakness
  • 1151025 2023-001
    Material Weakness
  • 1151026 2023-006
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
21.027 Coronavirus State and Local Fiscal Recovery Funds $1.40M
93.391 Covid-19 Activities to Support State, Tribal, Local and Territorial (stlt) Health Department Response to Public Health Or Healthcare Crisis $1.26M
93.394 Cancer Detection and Diagnosis Research $816,528
21.027 Covid-19 Coronavirus State and Local Fiscal Recovery Funds $609,195
93.310 Trans-Nih Research Support $313,490
93.889 National Bioterrorism Hospital Preparedness Program $270,452
16.560 National Institute of Justice Research, Evaluation, and Development Project Grants $187,525
93.323 Covid-19 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $167,045
93.350 National Center for Advancing Translational Sciences $164,703
93.994 Maternal and Child Health Services Block Grant to the States $119,852
93.368 21st Century Cures Act - Precision Medicine Initiative $94,609
93.838 Lung Diseases Research $93,061
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $80,571
93.855 Allergy and Infectious Diseases Research $72,630
93.351 Research Infrastructure Programs $67,407
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $64,097
93.396 Cancer Biology Research $56,813
12.420 Military Medical Research and Development $55,493
93.226 Research on Healthcare Costs, Quality and Outcomes $36,564
93.865 Child Health and Human Development Extramural Research $29,653
93.393 Cancer Cause and Prevention Research $17,681
93.307 Minority Health and Health Disparities Research $15,122
93.172 Human Genome Research $15,121
93.397 Cancer Centers Support Grants $14,078
93.866 Aging Research $11,855
93.273 Alcohol Research Programs $10,732
14.218 Community Development Block Grants/entitlement Grants $10,044
93.837 Cardiovascular Diseases Research $8,921
93.361 Nursing Research $7,645
93.667 Social Services Block Grant $7,551
93.839 Blood Diseases and Resources Research $3,217
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $597
93.395 Cancer Treatment Research $512
93.946 Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs $-697
93.859 Biomedical Research and Research Training $-2,184
93.242 Mental Health Research Grants $-20,481